PCTP

PC-TP (PCTP/StarD2) is a soluble START-domain lipid transfer protein that functions as a phosphatidylcholine sensor coupling membrane lipid status to metabolic and signaling outcomes. It catalyzes intermembrane phosphatidylcholine transfer in vitro and stimulates the long-chain acyl-CoA thioesterase activity of its physical partner Them2 in a Them2-dependent epistatic manner to promote hepatic fatty acid oxidation, gluconeogenesis, and suppress insulin sensitivity (PMID:17704541, PMID:24732803, PMID:18347010). PC-TP directly binds and represses PPARδ transcriptional activity in a phosphatidylcholine-ligand-dependent fashion, with PC-binding-site mutations abolishing both the interaction and repression (PMID:37173315). In platelets, PC-TP selectively mediates PAR4-dependent activation and dense granule secretion through Ca²⁺/PKC signaling, with its expression controlled transcriptionally by RUNX1 and post-transcriptionally by miR-376c (PMID:24216752, PMID:28676520, PMID:33770537).

1. 2007 High

   Identifying PC-TP's direct binding partners Them2 and Pax3 established that PC-TP is not merely a lipid shuttle but a protein–protein interaction hub that enhances Them2 thioesterase activity, linking lipid transfer to acyl-CoA metabolism.

   Evidence Yeast two-hybrid, pulldown, colocalization, and in vitro reconstitution of Them2 activity enhancement by recombinant PC-TP

   PMID:17704541

   Open questions at the time

   • Structural basis of PC-TP–Them2 interaction not resolved
   • Whether PC binding by PC-TP is required for Them2 activation was not tested
   • Pax3 coactivation mechanism was not further dissected
2. 2008 High

   Demonstrating that Pctp−/− mice have enhanced hepatic insulin sensitivity and altered substrate utilization revealed that PC-TP normally functions to limit insulin action and promote glucose output, positioning it as a metabolic regulator in vivo.

   Evidence Hyperinsulinemic-euglycemic clamp, indirect calorimetry, and isotope tracer studies in Pctp−/− mice

   PMID:18347010

   Open questions at the time

   • Whether the metabolic phenotype is cell-autonomous to hepatocytes was not established
   • Signaling intermediates between PC-TP and insulin pathway not identified
3. 2008 High

   An in vitro transfer assay confirmed PC-TP catalyzes intermembrane phosphatidylcholine transfer and identified small-molecule inhibitors, validating the enzymatic activity as a druggable target.

   Evidence Fluorescence quench transfer assay and high-throughput screen of ~115,000 compounds

   PMID:18762160

   Open questions at the time

   • In vivo efficacy of inhibitors not demonstrated
   • Selectivity of inhibitors for PC-TP over other START-domain proteins not fully characterized
4. 2009 High

   Finding that Pctp−/− mice have enlarged BAT mitochondria and increased thermogenesis extended PC-TP's metabolic role beyond liver, showing it restrains mitochondrial fatty acid oxidation in brown adipose tissue.

   Evidence Pctp−/− mouse BAT histology, oxygen consumption in cultured brown adipocytes, adenoviral Pctp rescue

   PMID:19502644

   Open questions at the time

   • Whether BAT phenotype is Them2-dependent was not tested
   • Mechanism linking PC-TP to mitochondrial morphology unknown
5. 2013 High

   Showing that PC-TP selectively mediates PAR4- but not PAR1-dependent platelet activation, with miR-376c as a post-transcriptional regulator, revealed a receptor-specific platelet signaling role entirely distinct from its hepatic metabolic functions.

   Evidence PC-TP inhibitor and siRNA depletion in human platelets and megakaryocytic cell lines, calcium mobilization and aggregation assays, miR-376c functional studies

   PMID:24216752

   Open questions at the time

   • Molecular mechanism of PAR4 selectivity over PAR1 not elucidated
   • Whether PC-TP lipid binding is required for platelet signaling not tested
6. 2014 High

   Genetic and pharmacological epistasis experiments demonstrated that PC-TP's regulation of hepatic fatty acid oxidation is fully Them2-dependent, resolving whether PC-TP acts through its lipid transfer activity alone or through its protein partner.

   Evidence Primary hepatocyte cultures from Pctp−/− and Them2−/− mice, chemical PC-TP inhibition in Them2−/− cells, fatty acid oxidation and gluconeogenesis assays

   PMID:24732803

   Open questions at the time

   • Whether PC-TP delivers PC to Them2 as a substrate or acts as an allosteric activator not distinguished
   • Stoichiometry and kinetics of the PC-TP–Them2 complex not characterized
7. 2017 High

   Identification of RUNX1 as a direct transcriptional activator of PCTP connected the megakaryocyte lineage transcription factor to PC-TP-dependent platelet function and provided a mechanism for lineage-specific PCTP expression.

   Evidence DNA-protein binding studies, luciferase promoter reporter, RUNX1 overexpression/knockdown in HEL cells

   PMID:28676520

   Open questions at the time

   • Whether RUNX1-driven PCTP expression is sufficient to modulate PAR4-dependent platelet reactivity in vivo not shown
   • Other transcription factors regulating PCTP in hepatocytes not identified
8. 2017 Medium

   Showing that Pctp−/− mice are protected from MCD diet-induced microvesicular steatosis and liver injury, independently of Them2, suggested a Them2-independent role for PC-TP's lipid transfer activity in stabilizing small lipid droplets under steatohepatitic stress.

   Evidence Pctp−/− MCD diet model, histopathology, lipid droplet quantification, c-Jun activation measurement

   PMID:28385694

   Open questions at the time

   • Them2-independence inferred indirectly; double-KO not performed
   • Direct evidence that PC transfer to lipid droplet membranes is the causative mechanism is lacking
9. 2021 Medium

   Extending platelet studies showed PC-TP promotes dense (but not alpha) granule secretion downstream of multiple agonists via Ca²⁺ and PKC, broadening its platelet role beyond PAR4 selectivity to a general dense granule secretion pathway.

   Evidence Pharmacological PC-TP inhibition in human platelets, dense/alpha granule secretion assays, calcium and PKC activity measurements with multiple agonists

   PMID:33770537

   Open questions at the time

   • Genetic confirmation (siRNA or KO platelets) for the broader agonist panel not provided
   • How PC-TP interfaces with Ca²⁺/PKC signaling machinery is unknown
10. 2023 High

    Demonstrating that PC-TP directly binds PPARδ (but not PPARα or PPARγ) in a PC-ligand-dependent manner and represses its transactivation established PC-TP as a nuclear receptor corepressor whose regulatory activity depends on its lipid cargo.

    Evidence In-cell protein complementation, co-IP in hepatocytes, PC-binding-site mutagenesis, PPARδ reporter assay, hepatocyte-specific Pctp knockdown mice

    PMID:37173315

    Open questions at the time

    • Whether PC-TP enters the nucleus or sequesters PPARδ in the cytoplasm is unresolved
    • Identity of endogenous PC species that regulate the PC-TP–PPARδ interaction not determined

• Major open questions include the structural basis of PC-TP's interactions with Them2 and PPARδ, whether its lipid-transfer and protein-interaction functions can be genetically separated in vivo, and the mechanism by which PC-TP selectively controls dense granule but not alpha granule secretion in platelets.
• No co-crystal structure of PC-TP with Them2 or PPARδ
• Separation-of-function mutations distinguishing lipid transfer from protein interaction not generated in vivo
• Platelet-specific conditional KO studies have not been performed